HEAD-TO-HEAD STUDY SHOWS ORAL FERRIC MALTOL (FERACCRU®) MAY BE AN ALTERNATIVE TREATMENT TO INTRAVENOUS (IV) FERRIC IRON, OFFERING A REAL ALTERNATIVE OPTION TO HOSPITAL ADMINISTRATION FOR PATIENTS WITH IRON DEFICIENCY ANAEMIA (IDA) AND INACTIVE INFLAMMATORY BOWEL DISEASE (IBD)
22 October 2019
We are a leading European specialist pharmaceutical company with a direct commercial presence in all major European markets. In 2019, Norgine generated >€425 million in net product sales, growing by 7 per cent since 2018.
We employ over 1,300 people across our commercial, development and manufacturing operations. We manage all aspects of product development, production, marketing, sales and supply.
Our approach and infrastructure is integrated and focused on ensuring that we win and deliver upon partnership opportunities for growth.
We are headquartered in the Netherlands.
Overall, we have sites and offices in the UK (Harefield and Hengoed), France (Rueil and Dreux), Germany (Wettenberg), Belgium (Heverlee), The Netherlands (Amsterdam), Nordics (Copenhagen), Switzerland (Luzern), Austria (Vienna), Italy (Milan), Portugal (Lisbon) and Spain (Madrid). Outside Europe, we have offices in Australia (Sydney) and New Zealand.
We employ over 1,300 employees. We have demonstrated manufacturing, clinical development, medical, pharmacovigilance, regulatory, market access, sales and marketing expertise across Europe, Australia and New Zealand.
Partnering is core to our business. Our approach to partnering is flexible which helps to meet the challenges faced by the pharmaceutical sector. We find and work with partners with complementary skills and a shared vision for improving healthcare and the lives of patients and their carers.